Docoh
Loading...

IOVA Iovance Biotherapeutics

News

From Benzinga Pro
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Dec. 3, 2021: EDIT, TSLA, LPSN, FB, NET, IOVA, BLFY, AMZN
6 Dec 21
Hedge Funds, Trading Ideas, General
EDITAS MEDICINE INC (EDIT) - 217800 TESLA INC (TSLA) - 119256 LIVEPERSON INC (LPSN) - 229442 FACEBOOK INC (FB) - 114499 CLOUDFLARE INC (NET) - 179031 IOVANCE BIOTHERAPEUTICS INC (IOVA) - 25500 BUTTERFLY NETWORK
Cathie Wood's ARK Invest Posts Fund Sales For Wednesday, Dec. 1, 2021: SHOP, IOVA, REGN, CDXS, INCY, COIN, OPEN, AMZN, LMT
2 Dec 21
Hedge Funds, Trading Ideas, General
SHOPIFY INC (SHOP) - 34151 IOVANCE BIOTHERAPEUTICS INC (IOVA) - 42230 REGENERON PHARMACEUTICALS INC (REGN) - 6460 CODEXIS INC (CDXS) - 121400 INCYTE CORP (INCY) - 187064 COINBASE GLOBAL INC (COIN) -
Cathie Wood's ARK Invest Posts Fund Sales For Tuesday, Nov. 30, 2021: Z, PRLB, TSLA, COIN, U, FTCH, CDXS, CSTL, INCY, IOVA, REGN, PINS
1 Dec 21
Hedge Funds, Trading Ideas, General
ZILLOW GROUP INC (Z) - 10231 PROTO LABS INC (PRLB) - 4749 TESLA INC (TSLA) - 30034 COINBASE GLOBAL INC (COIN) - 158437 UNITY SOFTWARE INC (U) - 325987 FARFETCH LTD (FTCH) - 11744 CODEXIS INC (CDXS) -
Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers
15 Nov 21
Biotech, News, Health Care, Movers, Trading Ideas, General
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Nov. 12, 2021: Z, LMT, IOVA, CLLS, CDXS, REGN, U
15 Nov 21
Hedge Funds, Trading Ideas, General
Zillow Group (Z) Lockheed Martin (LMT) Iovance Biotherapeutics (IOVA) Cellectis (CLLS) Codexis (CDXS) Regeneron Pharmaceuticals (REGN) Unity Software (U)
70 Biggest Movers From Friday
15 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4 sales guidance above estimates.
Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial
12 Nov 21
Biotech, News, Health Care, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Friday's Intraday Session
12 Nov 21
Intraday Update, Markets, Movers
48 Stocks Moving In Friday's Mid-Day Session
12 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares climbed 41% to $9.28 after the company reported better-than-expected Q3results and issued Q4 sales guidance above estimates.
Iovance Biotherapeutics Announces Clinical Data For Tumor Infiltrating Lymphocyte (TIL) Cell Therapy In Multiple Solid Tumors At Society For Immunotherapy Of Cancer (SITC) Annual Meeting
9 Nov 21
News, FDA, Events
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the publication of abstracts with clinical data for
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Nov. 5, 2021: PRLB, NSTG, Z, PYPL, IOVA, CSTL, REGN, PINS, NVDA
8 Nov 21
Hedge Funds, Trading Ideas, General
Proto Labs (PRLB) NanoString Technologies (NSTG) Zillow Group (Z) PayPal Holdings (PYPL) Iovance Biotherapeutics (IOVA) Castle Biosciences (CSTL) Regeneron Pharmaceuticals (REGN) Pinterest
Cathie Wood's ARK Invest Posts Fund Sales For Thursday, Nov. 4, 2021
5 Nov 21
Hedge Funds, Trading Ideas, General
Proto Labs (PRLB) Tesla (TSLA) Zillow (Z, ZG) Unity Software (U) Lockheed Martin (LMT) Castle Biosciences (CSTL) Iovance Biotherapeutics (IOVA) Opendoor Technologies (OPEN)
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $43
5 Nov 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $46 to $43.
Iovance Biotherapeutics Q3 EPS $(0.55) Misses $(0.53) Estimate
4 Nov 21
Earnings, News
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.53) by 3.77 percent. This is a 37.5 percent decrease over losses of $(0.40) per
Cathie Wood's ARK Invest Posts Fund Sales For Wednesday, Nov. 3, 2021
4 Nov 21
Hedge Funds, Trading Ideas, General
Proto Labs (PRLB) Tesla (TSLA) Zillow (Z, ZG) Lockheed Martim (LMT) Unity Software (U) Castle Biosciences (CSTL) Iovance Biotherapeutics (IOVA) Regeneron (REGN)
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
4 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK
Earnings Scheduled For November 4, 2021
4 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
Cathie Wood's ARK Invest Posts Fund Sales For Tues, Nov. 2, 2021: TSLA, LMT, PLTR, U, CSTL, IOVA, NSTG, PINS
3 Nov 21
Hedge Funds, Trading Ideas, General
Tesla (TSLA) - 80,100 Lockheed Martin (LMT) - 7,700 Palantir Technologies (PLTR) - 847,901 Unity Software (U) - 178310 Castle Biosciences (CSTL) - 8,174 Iovance
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Nov. 1, 2021: LMT, U, PYPL, TAK, CSTL, IOVA, TXG, NSTG, VEEV, PLTR, PINS, NVDA
2 Nov 21
Hedge Funds, Trading Ideas, General
Lockheed Martin (LMT) - 10,400 Unity Software (U) - 90,958 PayPal Holdings (PYPL) - 1,855 Takeda Pharmaceutical (TAK) - 101,857 Castle Biosciences (CSTL)
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Oct. 29, 2021: PTON, SLGCW, NSTG, TAK, IOVA, VEEV
1 Nov 21
Hedge Funds, Trading Ideas, General
Peloton Interactive (PTON) - 488,016 SomaLogic (SLGCW) - 548,744 Nanostring Technologies (NSTG) - 68,891 Takeda Pharmaceuticals (TAK) - 399,588 Iovance Biotherapeutics

Press releases

From Benzinga Pro
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19 Nov 21
Markets, Press Releases
SAN CARLOS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
13 Nov 21
News, Press Releases
Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30%
Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting
9 Nov 21
News, Health Care, Press Releases
TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer 21.4% Overall Response Rate (ORR) for TIL Therapy in Advanced,
Iovance Biotherapeutics to Present at Upcoming Conferences
8 Nov 21
News, Health Care, Press Releases
SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates
4 Nov 21
Earnings, Press Releases
SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte,
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021
25 Oct 21
News, Press Releases
SAN CARLOS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter
Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting
18 Oct 21
News, Press Releases
Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumabin Immune-Checkpoint Inhibitor Naïve Patients with Advanced Cancers Poster for TIL Therapy in Advanced, Immune Checkpoint Inhibitor-Treated
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
1 Oct 21
News, Press Releases
Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune Checkpoint Inhibitor-Naïve Patients with Advanced Cancers Poster for LN-145 Monotherapy in Advanced, Immune
Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard
28 Sep 21
News, Health Care, Press Releases
Ribbon Cutting to be Led by Patient Advocacy Organizations, Caregivers, and Key Stakeholders Largest and First Centralized, Scalable, State-of-the-Art Facility with the Potential to Manufacture TIL Cell Therapies for
Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC)
23 Sep 21
Health Care, Press Releases, General
First Patient Infused with TIL Cell Therapy Manufactured at iCTC SAN CARLOS, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel